JAZZ vs. PFE: Jazz Pharmaceuticals vs. Pfizer Stock Comparison
How do Jazz Pharmaceuticals (JAZZ) and Pfizer (PFE) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Jazz Pharmaceuticals (JAZZ) and Pfizer (PFE) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
| Profile Item | JAZZ | PFE |
|---|---|---|
| Name | Jazz Pharmaceuticals plc | Pfizer Inc. |
| Country/Region | Ireland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 15.07 billion USD | 167.52 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 1, 2007 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | JAZZ | PFE |
|---|---|---|
| Total Return (1Y) | 84.44% | 28.65% |
| Total Return (3Y, Annualized) | 27.57% | 6.41% |
| Total Return (5Y, Annualized) | 12.88% | -3.98% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Pfizer (PFE) is heavily traded at around 33.67M shares per day, whereas Jazz Pharmaceuticals (JAZZ) sees a more moderate 878.80K — larger orders in the latter may require more patience and tighter control over order sizing.
| Metric | JAZZ | PFE |
|---|---|---|
| Volatility (1Y, Annualized) | 38.74% | 21.72% |
| Beta (5Y) | 0.33 | 0.35 |
| Max Drawdown (5Y) | -42.03% | -58.96% |
| Avg. Volume (3M) | 878.80K | 33.67M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | JAZZ | PFE |
|---|---|---|
| Sharpe Ratio (1Y) | 2.07 | 1.12 |
| Sortino Ratio (1Y) | 4.14 | 1.73 |
Profitability
ROE (TTM)
Both Jazz Pharmaceuticals (JAZZ) at 5.05% and Pfizer (PFE) at 4.47% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.47%
- Max
- 109.18%
- Q3
- 6.23%
- PFE
- 4.47%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Pfizer (PFE) at 6.34% retains a top-quartile share of revenue as profit, ahead of Jazz Pharmaceuticals (JAZZ) at 4.37%, which keeps about the industry-typical share.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.34%
- Max
- 18.05%
- PFE
- 6.34%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Jazz Pharmaceuticals (JAZZ) at 30.17% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.38%
- Max
- 83.12%
- PFE
- 33.38%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | JAZZ | PFE |
|---|---|---|
| ROE (TTM) | 5.05% | 4.47% |
| ROA (TTM) | 6.92% | 5.59% |
| Net Margin (TTM) | 4.37% | 6.34% |
| Operating Margin (TTM) | 30.17% | 33.38% |
| Gross Margin (TTM) | 91.10% | 74.90% |
Growth
Revenue Growth
Jazz Pharmaceuticals (JAZZ) at 4.88% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Pfizer (PFE) at -3.55% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | JAZZ | PFE |
|---|---|---|
| Revenue Growth (YoY) | 4.88% | -1.65% |
| Revenue Growth (3Y CAGR) | 5.26% | -14.80% |
| EPS Growth (YoY) | -167.51% | -3.55% |
| EPS Growth (3Y CAGR) | -- | -37.12% |
Financial Strength
Current Ratio (MRQ)
Both Jazz Pharmaceuticals (JAZZ) at 1.82 and Pfizer (PFE) at 1.42 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.42
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- PFE
- 1.42
- Min
- 0.10
Debt / Equity (MRQ)
Both Jazz Pharmaceuticals (JAZZ) at 1.35 and Pfizer (PFE) at 0.71 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.71
- Max
- 1.42
- PFE
- 0.71
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | JAZZ | PFE |
|---|---|---|
| Current Ratio (MRQ) | 1.82 | 1.42 |
| Debt / Equity (MRQ) | 1.35 | 0.71 |
| Net Debt / EBITDA | 1.39 | 1.97 |
Dividends
Dividend Yield (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.30%
- PFE
- 7.30%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%).
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
245.71%
- PFE
- 245.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | JAZZ | PFE |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 7.30% |
| Dividend Payout Ratio (TTM) | 0.00% | 245.71% |
Valuation
P/E Ratio (TTM)
Pfizer (PFE) at 41.99 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
41.99
- Max
- 85.34
- Q3
- 43.46
- PFE
- 41.99
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Jazz Pharmaceuticals (JAZZ) at 3.19 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- PFE
- 2.63
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Jazz Pharmaceuticals (JAZZ) at 3.59 and Pfizer (PFE) at 1.88 are valued close to their industries’ norm against book — neither stands out from peers.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.88
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- PFE
- 1.88
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | JAZZ | PFE |
|---|---|---|
| P/E Ratio (TTM) | 69.46 | 41.99 |
| P/S Ratio (TTM) | 3.19 | 2.63 |
| P/B Ratio (MRQ) | 3.59 | 1.88 |
| Free Cash Flow Yield (TTM) | 11.16% | 7.76% |